Company Revenue

The company grew 5% in the second quarter of 2023 as it sustained its recent run of improved orthopedic sales...

Today we released our public and private orthopedic company sales estimates along with Joint Replacement, Spine, Trauma, Sports Medicine, Orthobiologics...

The company grew in the low single digits for its 2023 fiscal year, but its expansive technology ecosystem is a...

The company's 1Q23 orthopedic sales declined slightly as Bioventus embarks upon a quarters-long turnaround....

The company grew its orthopedic business 9% in 1Q23, driven by favorable order timing and contributions from new products....

The company grew over 45% in 1Q23 as it further penetrates the large, underserved bunion surgical procedure market....

The company grew 26% in 1Q23 against strong comps than most of the orthopedic industry, but opted to not increase...

The company grew 11.1% on a pro forma basis in 1Q23, driven by strength across its businesses and no major...

The company grew more than 30% in the first quarter of 2023 despite ongoing staffing challenges at pediatric hospitals....

The company grew 20% in 1Q23 due to improving procedure volumes, competitive rep recruiting and robotic pull-through....